FTC Orders Hikma To Divest Generics Rights In $5M Deal
The Federal Trade Commission on Friday ordered Hikma Pharmaceuticals PLC to sell off its rights in five generic drug products, including treatments for chickenpox and ulcers, to go through with its...To view the full article, register now.
Already a subscriber? Click here to view full article